Recent

% | $
Quotes you view appear here for quick access.

Novadaq Technologies Inc. Message Board

buzzybob 60 posts  |  Last Activity: Feb 2, 2016 7:58 AM Member since: Mar 16, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    earnings dateFeb 17

    by vonpezel Feb 1, 2016 7:27 PM
    buzzybob buzzybob Feb 2, 2016 7:58 AM Flag

    Glad to hear it's a little earlier than last year, when there were, accounting-wise, too many moving and negative parts from the Lifecell sales agreement dissolution. I see this as a positive nod to business normalcy.
    Buzz

  • Reply to

    Downgrade this morning?

    by bridgejumper08 Jan 14, 2016 10:32 AM
    buzzybob buzzybob Jan 14, 2016 1:54 PM Flag

    Hi, GSA,
    I think it's possible that the current drop is a play to make the remaining 5k $12.50 call options expire worthlessly tomorrow, January 15th.
    Regards, Buzz

  • buzzybob buzzybob Jan 14, 2016 1:44 PM Flag

    I think the current drop is a play to make the remain 5K call options expire worthlessly tomorrow, January 15th.

    regards,
    Buzz

  • This talk was short, 22 minutes, but Arun managed to deliver it with nary a pause. Slides were provided and helpful. He started with a by now typical description of SPY technology, Novadaq’s devices, and the medical applications targeted. Following are some highlights of the remainder.

    SPY Technology Procedures 200,000 / Installed Base - 650 Standalone - 1700 Firefly

    Charts of financial performance - The new $20M Q4 2015 revenue bar impressive towers over the preceding ones - until you realize the the axis isn’t zero based. Still, a doubling over two years isn’t bad.

    Novadaq’s approach to value based healthcare: fewer complications, fewer re-admissions, fewer repeat surgeries, newer/better procedures. Tables of comparative complication rates with and without SPY were given for breast reconstruction and colon resection with associated costs.

    Slide 17 (an eye opener) - a table detailing hospital readmissions (and costs) for cholecystectomy, colorectal resection, wound debridement, and lower extremity amputation. The readmission rates for these range from 9.5% to 22.8% and the total cost for them is estimated to be over $15B! I had no idea readmissions for cholecystectomy (gall bladder removal) was 10% and costs $4B. (A similar surprise for wound debridement.) Use of SPY technology in all these procedures could slash readmission rates. Look at the replay for this slide alone.

    The key applications opportunity slide contains no additions and has the same numbers as the presentation last year - two million procedures total.

    Growth drivers:
    New products (handheld SPY and 5mm endoscope) in 2016.
    New imaging molecules for tumors are on the way for 2017.
    International sales to kick in in the second half of 2016.

    All in all, encouraging.

    Buzz

  • Reply to

    radiology

    by nisku98 Nov 27, 2015 9:29 AM
    buzzybob buzzybob Dec 22, 2015 11:07 AM Flag

    My response does appear a bit snarky (unintended). But the "open your eyes" phrase rolled out too easily from the analogy! Sorry, nancy!

  • Reply to

    radiology

    by nisku98 Nov 27, 2015 9:29 AM
    buzzybob buzzybob Dec 22, 2015 8:00 AM Flag

    No, LUNA can't replace an xray based-machine in all cases. However, you don't first check the breaker panel to see if the lights are working, you just flip the wall switch and open your eyes.

  • Reply to

    radiology

    by nisku98 Nov 27, 2015 9:29 AM
    buzzybob buzzybob Nov 27, 2015 1:26 PM Flag

    Not to mention LUNA's advantage of not exposing patients and staff to x-ray radiation. Unconscionable.
    Buzz

  • Reply to

    Filled the gap up

    by e11ndofwar Nov 19, 2015 7:03 PM
    buzzybob buzzybob Nov 27, 2015 7:37 AM Flag

    Of particular note to followers of Cardica, over that period (9/30/2015) Broadfin Capital increased its number of Novadaq shares from 520k to 1.90M. They now own 3.4% of Novadaq. I'm not saying whether that's a good thing or a bad thing!

    The top five holders are FIDELITY (FMR) at 11.5%, JPMORGAN CHASE at 11.2%, PRIMECAP at 8.8%., JANUS at 8.6%, and CAPITAL RESEARCH GLOBAL at 7.6%. That’s 48% of the pie, folks. Over the period all these companies pretty much stood pat, except JPMC which dropped its holdings from 12.8% to 11.2%.

    Buzz

  • Reply to

    today's Canaccord webcast

    by vonpezel Nov 19, 2015 12:37 PM
    buzzybob buzzybob Nov 19, 2015 12:57 PM Flag

    No problems here. Mac/Safari.
    Buzz

  • Reply to

    Is it Novadaq or the market??

    by e11ndofwar Nov 17, 2015 10:24 AM
    buzzybob buzzybob Nov 18, 2015 3:11 PM Flag

    Pezel,
    I don't see any action regarding Stryker. The only one I noticed was relating to Karl Storz efforts to invalidate claims in Novadaq's Patent Number 7,420,151.
    Buzz

  • Reply to

    Is it Novadaq or the market??

    by e11ndofwar Nov 17, 2015 10:24 AM
    buzzybob buzzybob Nov 18, 2015 12:21 PM Flag

    Despite many positives put forth in recent communications, there are some headwinds. It's clear from listening to the Sifel Conference webcast that one investor concern is related to dropping kit ASP, mainly due to the conversion of placed units to capital sales units.

    Another is lack of progress on LUNA sales growth. One question put forward was if using LUNA might actually decrease wound care clinic revenue by decreasing the number of hyperbaric sessions required. (This concern will probably dwindle as results-based reimbursement takes hold.)

    Also of concern is the coming 50% increase in sales staff, which is likely to, temporarily, result in reduced overall productivity.

    Not a subject of recent talks is the fact that many of us invested when the company looked like positive cash flow was right around the corner. Ever since the Lifecell troubles began, that horizon has continuously receded. Accelerated growth in the near future may change that, but it remains to be seen.

    Regards, Buzz

  • Reply to

    investor day

    by e11ndofwar Nov 16, 2015 9:00 AM
    buzzybob buzzybob Nov 17, 2015 8:44 AM Flag

    I agree that the FILM study is exciting; the detailed explanation of the why it is so urgent to map and biopsy these sentinel lymph nodes was excellent and should be viewed by all who have only a vague idea of the utility of doing so.

    Buzz

  • BioTuesdays’ interview of Arun Menawat on 10/20/2015 was noteworthy for at least two points. 1) The newly announced 5mm endoscope should allow surgeons increased utilization of Pinpoint; 35% to 40% of surgeries require the smaller size. 2) Novadaq is still actively developing the radiopharmaceutical imaging product (Trapper) and the laser doppler flow imaging product. Nerve imaging efforts will be discussed later next year.

    A duplicate post on IV will provide a link.

    Regards, Buzz

  • buzzybob buzzybob Nov 6, 2015 7:44 AM Flag

    Hi GSA,
    I wish I could attend Investors Day, but family life trumps financial life, at least this year! I'm looking forward to hearing any tidbits you and Pezel may pick up. You might ask why PILLAR III is coming along more slowly than expected (just about the only negative item in the whole cc). My concern is slippage; even after study's end, official publication of PILLAR II's results took a lot longer than expected.
    Have a great trip,
    Buzz

  • buzzybob buzzybob Nov 4, 2015 8:58 AM Flag

    GSA,

    FYI, about 5k of the 10k of the $12.50 Jan 16 Call open interest is now history, the 10k $10.00 Put remains intact.

    Buzz

  • Reply to

    Q & A

    by e11ndofwar Oct 29, 2015 9:25 AM
    buzzybob buzzybob Oct 29, 2015 10:38 AM Flag

    Typical traditional 4th quarter revenue runs sequentially at about 19% over the 3rd quarter result. That would put the upcoming 4th's revenue at about $20.25M. Currently, the analyst estimates call for $19.09M average, with the high estimate being $20.32M. Sounds like they're going for the high end.

    Buzz

  • buzzybob buzzybob Oct 14, 2015 11:18 AM Flag

    Interesting scenario, GSA, but my question is, who is on the other side of this transaction, selling all these calls and puts?!!!!

    Regards, Buzz

  • Reply to

    buzztbob

    by e11ndofwar Oct 13, 2015 2:53 PM
    buzzybob buzzybob Oct 14, 2015 6:46 AM Flag

    I am hesitant to believe these are "real" trades. The trade volume is so anomalous on both the call and put sides that it appears likely all bets were placed by the same entity. These are approaching contract volumes usually reserved for companies the size of AAPL. A billboard, perhaps?

  • buzzybob buzzybob Oct 10, 2015 3:39 PM Flag

    GSA, my comment was directed at Pezel's comment that Arun should wake up. Getting a FDA label is an ordeal and I'm sure Novadaq is awake. It just can't speak. Yet.

    Buzz

  • buzzybob buzzybob Oct 8, 2015 5:50 PM Flag

    I'm unsure if Novadaq has FDA approval for this application yet. If not, it isn't allowed to advertise off-label use.
    Buzz

NVDQ
9.10-0.19(-2.05%)Feb 12 4:00 PMEST